Comparison of pregnancy outcomes and physical conditions of infants in patients with gestational diabetes mellitus treated with metformin and insulin: a meta-analysis study
Abstract
BACKGROUND: Gestational diabetes mellitus (GDM) is a common complication during pregnancy, which seriously affects the health of mothers and infants. Metformin and insulin are both commonly used therapeutic drugs, but the effects of the two on pregnancy outcomes and the physical condition of the infants remain undetermined. This study conducted a meta-analysis to compare the effects of two drugs in the treatment of gestational diabetes mellitus (GDM), providing a basis for clinical medication. METHODS: Our research systematically searched the PubMed, Embase, and Cochrane Library databases to include randomized controlled trials (RCTS) of metformin and insulin in the treatment of GDM. The search period was up to March 2025. Literature screening, data extraction and quality evaluation were independently completed by two researchers, and statistical analysis was performed using RevMan 5.4 software. RESULTS: Eventually, 8 RCTS were included, involving a total of 2,350 patients with GDM. Meta-analysis showed that the cesarean section rate in the metformin group was 26.3%, which was lower than 33.7% in the insulin group (RR = 0.78, 95%CI:0.75–0.81, P < 0.05). The incidence of gestational hypertension in the metformin group was 13.8% (26 out of 188 patients), which was lower than 18.6% (34 out of 183 patients) in the insulin group (RR = 0.74, 95% CI: 0.69–0.79, P < 0.05). The cesarean section rate was 30.9% (58/188) in the metformin group vs. 38.8% (71/183) in the insulin group (RR…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 2,350 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.